Sanctuary Advisors LLC Decreases Stake in Insulet Co. (NASDAQ:PODD)

Sanctuary Advisors LLC lessened its stake in shares of Insulet Co. (NASDAQ:PODD) by 1.5% in the third quarter, HoldingsChannel.com reports. The firm owned 4,051 shares of the medical instruments supplier’s stock after selling 63 shares during the quarter. Sanctuary Advisors LLC’s holdings in Insulet were worth $943,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in PODD. Blue Trust Inc. boosted its position in Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC bought a new position in shares of Insulet during the second quarter valued at about $32,000. Venturi Wealth Management LLC boosted its holdings in shares of Insulet by 633.3% during the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 133 shares during the period. UMB Bank n.a. boosted its holdings in shares of Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the period. Finally, TD Private Client Wealth LLC increased its holdings in Insulet by 32.6% during the 3rd quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 56 shares during the period.

Insider Buying and Selling at Insulet

In other news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PODD has been the subject of several research analyst reports. Citigroup increased their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. BTIG Research upped their price objective on shares of Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Wells Fargo & Company lifted their target price on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Raymond James increased their price target on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a research note on Monday, October 14th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and a consensus price target of $269.40.

Insulet Stock Performance

Shares of PODD opened at $266.57 on Monday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The stock has a market cap of $18.70 billion, a P/E ratio of 45.65, a P/E/G ratio of 4.12 and a beta of 1.21. The business’s 50 day moving average price is $254.48 and its 200-day moving average price is $223.25. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.77.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.